Alvotech – Revolutionizing Global Healthcare with Accessible and Affordable Biosimilars

The Silicon Review

Biologic medicines, or biologics, are created using biotechnology within living systems. These are large, complex molecules that require advanced techniques to produce and are often given through injections or infusions. On the other hand, traditional medicines are made from chemically synthesized small molecules, which are easier to produce and usually come in pill or capsule form. The growth of biologics comes from cutting-edge research, providing new and innovative treatments for various diseases.

While biologics offer groundbreaking treatment options for serious and life-threatening conditions, they are often expensive, limiting access for many patients. However, there’s a more affordable alternative emerging: biosimilars. These are biologic medicines that are very similar to previously approved biologics already available on the market. Biosimilars help by introducing competition; much like generic drugs did over 35 years ago, increasing access to essential treatments. This competition benefits not only patients by offering more affordable options but also health systems by reducing costs.

Alvotech is a company deeply aware of the life-changing impact biologics have had on healthcare. From insulin and vaccines to cancer therapies, biologics have transformed the way diseases are treated, improving the lives of countless patients worldwide. Alvotech is committed to making these vital biologic medicines more accessible by developing and producing high-quality, cost-effective biosimilars.

Driven by a strong belief in the power of biosimilars, Alvotech works with a clear mission: to make life-saving medicines available to more people. By lowering the cost of existing treatments, the company aims to support the sustainability of healthcare systems and free up resources for the development of the next wave of innovative biologics.

What Sets Alvotech Apart?

Alvotech stands out in the world of biosimilars through its unwavering dedication to making life-changing biologic medicines more accessible and affordable. What truly differentiates Alvotech is its relentless commitment to this mission, backed by a dynamic team of over 900 professionals spanning multiple countries. United by a shared purpose, Alvotech’s workforce operates as a cohesive global force, driven by the singular goal of expanding access to high-quality, cost-effective biologic treatments. This collective mission forms the very heart of Alvotech’s organizational culture, where diverse expertise and innovative thinking come together to drive real-world impact.

The company’s success is fueled by the passion, motivation, and empowerment of its people. Alvotech’s team mirrors the diversity of the global markets they serve, creating a work environment that is both collaborative and deeply engaged. The company brings together some of the brightest minds in the industry, investing strategically not only in cutting-edge scientific advancements but also in the continuous growth and development of its team. This unique blend of talent, creativity, and commitment ensures that Alvotech consistently delivers on its promise to patients and partners worldwide.

By cultivating a culture that values insight, creativity, and determination, Alvotech transforms its mission into a powerful, driving force for change. They are not just developing biosimilars—they are revolutionizing the accessibility of essential treatments, giving patients around the globe a chance at better health. Alvotech’s holistic approach to innovation and empowerment is what enables them to make such a profound difference, providing the foundation for a future where affordable biologics are within reach for all.

Advancing Access, Enriching Lives

Guided by scientific innovation, fueled by unwavering passion, and dedicated to the realm of biosimilars, Alvotech stands committed to enhancing treatment options globally. The company consistently assesses additional opportunities in its pipeline, aiming to provide a strategic and comprehensive array of therapeutic solutions to patients worldwide. Collaborating with Alvotech opens doors to a partner deeply devoted to developing and manufacturing top-tier, cost-competitive biosimilars.

Alvotech actively seeks commercial partners who share their fervor for expanding biosimilar access to patients globally and possess profound expertise to transform the promise of biosimilars into reality. The company is receptive to forming partnerships and licensing agreements for their biosimilar assets on a global scale. They firmly believe that through collaborative efforts, partners can harness the collective strengths each brings to the table, creating substantial value for their customers.Top of Form

Róbert Wessman | Founder & CEO

Róbert Wessman is the visionary behind Alvotech, known for his passion for improving patient lives and the global healthcare ecosystem, his unwavering focus and his ability to successfully combine operational efficiency with growth through strategic acquisitions. He recognized the potential early on for locating a biotechnology company in Iceland and founded Alvotech in 2013, further contributing to the pharmaceutical industry growth there.

Prior to founding Alvotech, Róbert Wessman transformed Actavis, originally a small domestic pharmaceutical company, into the fourth largest generics company in the world within seven years as CEO. He also founded Alvogen in 2009 as a US-based CMO prior to growing it into a top global generics company over the course of 6 years. In total over his more than 20-year career in the pharmaceutical industry, he has led over 50 strategic acquisitions and partnerships and established operations in over 60 countries around the world.